Gene network and canonical pathway analysis in prostate cancer: a microarray study by Savlı, Hakan et al.
EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 40, No. 2, 176-185, April 2008
Gene network and canonical pathway analysis in prostate 
cancer: a microarray study
Hakan Savli1,4*, Attila Szendrӧi2*, Imre Romics2 
and Balint Nagy3
1Department of Medical Genetics and Clinical Research Unit
Kocaeli University
Kocaeli 41380, Turkey
2Department of Urology
Semmelweis University
Budapest 1082, Hungary
3Genetic Laboratory
1st Department of Obstetrics and Gynecology
Semmelweis University
Budapest 1088, Hungary
4Corresponding author: Tel, 90-532-660-96-68;  
Fax, 90-262-303-80-16; E-mail, hakansavli@yahoo.com
*These authors contributed equally to this work.
Accepted 15  January 2008
Abbreviations: AR, androgen receptor; BPH, benign prostate 
hyperplasia; IGF, insulin-like growth factor; PCA, prostate cancer; 
PSA, prostate specific antigen
Abstract
The molecular mechanism playing a role in the devel-
opment of prostate cancer (PCA) is not well defined. We 
decided to determine the changes in gene expression 
in PCA tissues and to compare them to those in non- 
cancerous samples. Prostate tissue samples were col-
lected by needle biopsy from 21 PCA and 10 benign 
prostate hyperplasic (BPH) patients. Total RNA was 
isolated, cDNA was synthesized, and gene expression 
levels were determined by microarray method. In the 
progression to PCA, 738 up-regulated and 515 down- 
regulated genes were detected in samples. Analysis 
using Ingenuity Pathway Analysis (IPA) software re-
vealed that 466 network and 423 functions-pathways 
eligible genes were up-regulated, and 363 network and 
342 functions-pathways eligible genes were down-re-
gulated. Up-regulated networks were identified 
around IL-1β  and insulin-like growth factor-1 (IGF-1) 
genes. The NFKB gene was centered around two up- 
and down-regulated networks. Up-regulated canon-
ical pathways were assigned and four of them were 
evaluated in detail: acute phase response, hepatic fib-
rosis, actin cytoskeleton, and coagulation pathways. 
Axonal guidance signaling was the most significant 
down-regulated canonical pathway. Our data provide 
not only networks between the genes for understanding 
the biologic properties of PCA but also useful pathway 
maps for future understanding of disease and the con-
struction of new therapeutic targets.
Keywords: microarray analysis; prostate-specific an-
tigen; prostatic neoplasms
Introduction
Prostate cancer (PCA) is the second most com-
mon cancer in men. This tumor develops slowly, 
and successful screening protocols can help to 
reduce mortality and morbidity (Müller and Brenner, 
2006). Digital rectal examination and serum 
prostate specific antigen (PSA) determination are 
the most commonly used screening methods 
worldwide. PSA has an excellent sensitivity with a 
low specificity. There is a great interest to find 
more reliable diagnostic and prognostic markers. 
The molecular mechanism playing a role in the 
development of PCA is not known. The hetero-
geneity of PCA has been recognized for a long 
time and varies from asymptomatic to a rapidly 
fatal systemic malignancy (Hughes et al., 2005; 
Maitland and Collins, 2005). Molecular biological 
methods are used to determine similarities and 
differences, and obtain useful information for effec-
tive treatment and prognosis (Quinn et al., 2005).
    PCA is the leading cause of death in the US and 
in Europe. It is a heterogeneous disease and the 
outcome is difficult to predict. Digital rectal exami-
nation and serum PSA level measurements are the 
main tools in the diagnostic protocols.
    Molecular biological methods including immuno-
histochemistry, comparative genomic hybridization 
(CGH), CGH-array, microarray analysis, and quan-
titative real-time PCR determinations have been 
used in the search to determine the molecular 
mechanism of the developmentof PCA, and to find 
new diagnostic and prognostic markers (Hughes et 
al., 2005; Quinn et al., 2005).
Materials and Methods
Patients
Prostate tissue samples were obtained by trans-
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rectal ultrasound guided needle biopsy from non- 
treated 21 PCA (PCA) and 10 benign prostate 
hyperplasic (BPH) patients from October of 2005 to 
March of 2006. The selection of patients was 
based on digital rectal examinations and on serum 
PSA levels, and was confirmed by histological 
examination later. Gleason’s grades were as-
signed. The average age was 72.0 ± 8.8 years vs. 
64.3 ± 12.1 years, respectively. The Ethical Com-
mittee of Semmelweis University approved the 
study and all patients gave informed consent to be 
involved. Prostate tissue samples were transferred 
to 1.5 ml Eppendorf tubes containing 0.5 ml of 
DNA/RNA Stabilization Reagent (Roche, Mann-
heim, Germany) following the biopsy, and these 
were kept at -85oC until the RNA isolation.
PSA determination
Pre-biopsy PSA levels were determined by micro-
particle enzyme immunoassay (MEIA) on an Abbott 
IMx using a PSA kit (Abbott Park, IL).
RNA isolation
During the RNA isolation tissue samples were 
placed to lysing matrix tubes containing 0.3 ml of 
RNA lysis buffer and were treated using a Fast-
Prep Bio101 tissue destroyer centrifuge (Thermo 
Savant, Holbrook, NY). A Perfect RNA Eukaryotic 
kit was used (Eppendorf, Hamburg, Germany) for 
RNA isolation from the samples according to the 
manufacturer’s instructions.
Microarray hybridizations
Applied Biosystems Human Genome Survey Ar-
rays V2.0, covering 29,098 genes, were used to 
determine the transcriptional profiles of 21 PCA 
and 10 BPH samples. DIG-UTP labelled cRNA 
was generated and linearly amplified from 2 μg 
total RNA using the Chemiluminescent RT-IVT 
Labeling Kit v 2.0 (Applied Biosystems, Foster City, 
CA) as described by the protocol. Array hybri-
dization, chemiluminescence detection, image ac-
quisition and analysis were performed using Ap-
plied Biosystems Chemiluminescence Detection 
Kit and Applied Biosystems 1700 Chemilumine-
scence Microarray Analyzer following the manufac-
turer’s instructions.
    Briefly, each microarray was first pre-hybridized 
at 55oC for 1 h in hybridization buffer with blocking 
reagent. Twenty μg DIG-labeled cRNA targets 
were first fragmented mixed with internal control 
target and hybridized to the prehybridized micro-
arrays in a volume of 1.5 ml at 55oC for 16 h. After 
hybridization, the arrays were washed with hybri-
dization wash buffer and chemiluminescence rinse 
buffer. Enhanced chemiluminescent signals were 
generated by incubating arrays with alkaline phos-
phatase conjugated anti-digoxigenin antibody fol-
lowed by incubation with Chemiluminescence En-
hancing Solution and a final addition of Chemil-
uminescence Substrate. Images were collected for 
each microarray using the ABI 1700 Chemilu-
minescent Microarray Analyzer. Images were auto- 
gridded and the chemiluminescent signals were 
quantified, corrected for background and spot and 
spatially normalized. Obtained data imported into 
GeneSpring 6.1  software for analysis (GeneSpring 
6.1, Silicon Genetics, Redwood City, CA). The fold 
changes were analyzed by filtering the dataset 
using P-value ＜ 0.01 and a signal-to-noise ratio ＞
2 for use in ANOVA statistical analysis. Additional 
filtering (minimum 2-fold change) was applied to 
extract the most these gene which were analyzed 
using Ingenuity Pathway Analysis (IPA) software 
(Ingenuity Systems, Redwood City, CA). Those 
genes with known gene symbols (HUGO) and their 
corresponding expression values were uploaded 
into the software. Each gene symbol was mapped 
to its corresponding gene object in the Ingenuity 
Pathways Knowledge Base. Networks of these 
genes were algorithmically generated based on 
their connectivity and assigned a score. The score 
is a numerical value used to rank networks 
according to how relevant they are to the genes in 
the input dataset but may not be an indication of 
the quality or significance of the network. The 
score takes into account the number of focus 
genes in the network and the size of the network to 
approximate how relevant this network is to the 
original list of focus genes. The network identified 
is then presented as a graph indicating the 
molecular relationships between genes/gene 
products. Genes are represented as nodes, and 
the biological relationship between two nodes is 
represented as an edge (line). The intensity of the 
node color indicated the degree of up- or 
down-regulation. Genes in uncolored notes were 
not identified as differentially expressed in our 
experiment and were integrated into the 
computationally generated networks on the basis 
of the evidence stored in the IPA knowledge 
memory indicating a relevance to this network. The 
node shapes denote enzymes ( ), phosphatases 
( ), kinases ( ), peptidases ( ), G-protein 
coupled receptor ( ), transmembrane receptor ( ), 
cytokines ( ), growth factor ( ), ion channel ( ), 
transporter ( ), translation factor ( ), nuclear 
receptor ( ), transcription factor ( ) and other 
( ). Canonical pathways analysis identified the 
178    Exp. Mol. Med. Vol. 40(2), 176-185, 2008
Table 2. Summarized real time PCR confirmation results of the four genes. 
Genes Ratios obtained by real-time PCR Ratios obtained by arrays 
IL-1β  (interleukin-1 beta precursor) 2418,673 (Up-regulated) 2,541 (Up-regulated) 
Chemokine (C-X-C motif) receptor 4       7,754 (Up-regulated) 2,006 (Up-regulated) 
Fas (TNF receptor superfamily, member 6)     44,663 (Up-regulated) 2,664 (Up-regulated)
Cyclin-dependent kinase inhibitor 1A (p21, Cip1)   221,168 (Down-regulated ) 3,153 (Down-regulated )
Table 1. List of the primers used for the quantitative RT-PCR.
p21 
TGA GCG ATG GAA CTT CGA CT
GAC AGT GAC AGG TCC ACA TGG
β2-Microglobulin
TGA CTT TGT CAC AGC CCA AGA TA 
AAT CCA AAT GCG GCA TCT TC
Fas   
ACT GTG ACC CTT GCA CCA AAT-
GCC ACC CCA AGT TAG ATC TGG
IL1β
GTGCTGAATGTGGACTCAATCC
TGACAGAGGAGGGTTTCTTAGAAC
CXCR4 
CCGCTTCTACCCCAATGACT
GCGAAGAAAGCCAGGATGAG
pathways, from the IPA library of canonical path-
ways, which were most significant to the input data 
set. The significance of the association between 
the data set and the canonical pathway was de-
termined based on two parameters: (1) A ratio of 
the number of genes from the data set that map to 
the pathway divided by the total number of genes 
that map to the canonical pathway and (2) a P  
value calculated using Fischer’s exact test deter-
mining the probability that the association between 
the genes in the data set and the canonical 
pathway is due to chance alone. 
Quantitative real-time PCR (Q-RT-PCR)
cDNA was synthesized using DNase-I-treated total 
RNA with a First Stand cDNA synthesis kit for 
RT-PCR (Roche Diagnostic Corp., Indianapolis, IN) 
according to the manufacturer’s instructions. Quan-
titative PCR were performed using a LightCycler 
(Roche) as reported previously (Savli et al., 2002) 
for determination of Fas, IL-1β , P21, and CXCR4 
gene expressions. β2-microglobulin gene was used 
as the internal control. Gene sequences are shown 
in Table 1. The Relative Quantification REST 
software package (SPSS, Chicago, IL) was used 
for the statistical evaluation of the data.
Results
Differentially expressed genes are shown in two 
separate tables. The 100 most up-regulated genes 
(PCA samples compared to BPH samples) are 
shown in Supplementary Table 1. The 100 most 
down-regulated genes (BPH samples compared to 
PCA samples) are shown in Supplementary Table 
2. Both sets of results were obtained as two-fold 
values. Table 2 indicates the gene expression 
results of four genes (Fas, IL-1β , P21, CXCR4), 
obtained by Real Time PCR and microarray 
methods. These results are in a good agreement.
    In the progression to PCA 738 up-regulated 
genes were detected. We investigated interactions 
using the Ingenuity Pathway Analysis (IPA) soft-
ware and found 466 network eligible genes and 
423 Functions-Pathways eligible genes. Figure 1 
shows the most significant three gene networks of 
over-expressed genes in PCA samples. Top func-
tions of these genes were related to cellular move-
ment, hematological system development, immune 
response, cell signaling, molecular transport, vita-
min and mineral metabolism, cancer, reproductive 
system,  gene expression. These networks  identi-
fied around IL-1β ,  IGF-1 and NFKB  genes. 
    Table 3 lists the top ten canonical pathways that 
are up-regulated. Supplementary Figure 1 shows 
the canonical pathway of acute phase response 
signaling, and Supplementary Figure 2 shows the 
canonical pathway of the coagulation system. Sup-
plementary Figure 3 shows the canonical pathway 
of hepatic fibrosis/hepatic stellate cell activation in 
diagrammatic form.
    In the progression to PCA 449 down-regulated 
genes were detected. We investigated interactions 
using the IPA and found 363 network eligible genes, 
and 342 Functions-Pathways eligible genes. Figure 
2 shows a gene network and down-regulated 
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genes in PCA. The main functions of the genes 
were related to cellular assembly and organization, 
connective tissue development and function, and 
neurological disease, and were identified around 
the NFKB gene. 
    Table 4 lists the top ten canonical pathways that 
are down-regulated. Supplementary Figure 4 shows 
the canonical pathway of antigen presentation and 
Supplementary Figure 5 shows the cellular lo-
calization of the genes and their functions in the 
axonal guidance signaling pathway.
Discussion
PCA is a heterogeneous disease and many mol-
ecular methods have been used in the search to 
determine the mechanism of the development of 
the disease, and to find new diagnostic and pro-
gnostic markers (Hughes et al., 2005; Quinn et al., 
2005). Our study has demonstrated new genetic 
networks and biological pathways in both up- and 
down-regulated gene expression levels. It should 
be kept in mind that there are certain limits to in 
Figure 1. Most significant three gene networks  of over-expressed 
genes in PCA samples.  Node (gene) and edge (gene relationship) 
symbols were described in the bottom part of the figure. The intensity 
of the node color-(red))  indicated the degree of up-regulation. Genes 
in uncolored notes were not identified as differentially expressed in 
our experiment and were integrated into the computationally gen-
erated networks on  the basis of the evidence stored in the IPA 
knowledge memory indicating a relevance to this network. The node 
shapes denote enzymes ( ), phosphatases ( ), kinases ( ), 
peptidases ( ), G-protein coupled receptor ( ), transmembrane 
receptor ( ), cytokines ( ), growth factor ( ), ion channel ( ), trans-
porter ( ), translation factor ( ), nuclear receptor ( ), 
transcription factor ( ) and other ( ).
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Table 3. List of the genes in most significantly up-regulated top ten canonical pathways.
Pathway -log(P-value) Ratio Molecules
Acute phase response signaling 1,33E+01 9,88E-02 TTR, ORM2, C1S, VWF, SAA2, SERPINA3, MAPK12, HRG, ORM1, FOS, RBP7, TF, F8, CFB, IL1B, SAA1, C4B
Hepatic fibrosis/hepatic stellate cell 
 activation 1,26E+01 1,15E-01
FGF2, MYL5, ACTA2 (includes EG:59), EGF, 
MYH11, MYL9, CXCL3, LY96, EDN1, CCL2, IGF1, IL1B,
EDNRA, AGTR1, PDGFRB
NRF2-mediated oxidative stress 
 response 7,54E+00 6,63E-02
CUL3, FOS, PRKCD, ACTA2 (includes EG:59), DNAJB7, 
DNAJC3, DNAJA2, DNAJC10, ACTG2, ACTC1, TXNRD1, BACH1
Actin cytoskeleton signaling 6,80E+00 5,06E-02
ARHGEF4, FGF2, MYL5, ACTA2 (includes EG:59), EGF,
MYH11, WASF1, MYL9, GPR65, PPP1R12B, ACTG2, ACTC1, 
PDGFRB
Leukocyte extravasation signaling 5,44E+00 5,32E-02 CDH5, MMP3, CXCR4, PRKCD, ACTA2 (includes EG:59), MMP11, ACTG2, MAPK12, MMP23A, ACTC1
Axonal guidance signaling 5,27E+00 3,42E-02 DPYSL2, CXCR4, MYL5, EGF, FZD1, EIF4E, MYL9,EPHA8, IGF1, PRKCD, FZD5, GLI1, PPP3CA, PDGFRB
Calcium signaling 5,12E+00 4,61E-02 MYL9, TPM1, TRPC1, ACTA2 (includes EG:59), MYL5, RCAN2, TPM2, MYH11, ACTC1, PPP3CA
Xenobiotic metabolism signaling 5,10E+00 4,38E-02 CUL3, MAOB, FMO2, CHST7, PPP2R2A, PRKCD, IL1B, UGT2B17, NRIP1, CES1 (includes EG:1066), MAPK12
Coagulation system 4,96E+00 1,43E-01 F8, F5, F9, VWF, F3
Complement system 4,96E+00 1,35E-01 C1S, CFB, CFI, C7, C4B
silico analysis. Since there are many different gene- 
gene interactions resulting from various cellular/ex-
perimental conditions, the edges denoted in the 
network may not represent the actual causal re-
lationship between genes. Moreover, the probe 
collection on a chip, which necessarily relies on the 
coverage and the accuracy of both genomic se-
quences and clone libraries, presents a serious 
constraint on its detection power (Liu et al., 2007). 
Furthermore, confounding factors such as low- 
abundance potential biomarkers could interfere 
with several groups of high-abundance proteins in 
human plasma in which a dynamic concentration 
range of protein component exists (Cho et al., 
2005).
  Analysis using IPA software revealed 738 up- 
regulated genes in the progression to PCA. These 
were 466 network eligible genes and 423 Func-
tions-Pathways eligible genes. Often individual genes 
were found in multiple categories of functions re-
lated to cancer development including cell-to-cell 
signaling and interaction, cell signaling, cell death, 
cellular growth and proliferation, andcellular move-
ment.
    One important gene network was identified 
around the IL-1β  gene (Figure 1). This gene has 
been reported to be a potent modulator of cellular 
differentiation and a suitable target for anticancer 
drug design in PCA (Albrecht et al., 2004). A group 
of chemokines (CCL20, CCL3, CXCL3, CXCL6, 
CCL14) were up-regulated around IL-1β . Chemo-
kines and their ligands are considered to have a 
significant role in tumor angiogenesis and cancer 
metastasis. CCL3, CXCL3, and CXCL6 were 
reported before in PCA (Akashi et al., 2006; Engl 
et al., 2006). In particular, CXCL3 were found to be 
highly up-regulated in our study. Other chemokines 
(MIP-3, MIP-4, MIP-1A, BCA-1, CC-1, MCP-1, 
TAFA-5, IP-9, CXCR4) were not identified on this 
network, but they were up- regulated in our study. 
The CXCR4 gene was reported as up-regulated in 
leukemia and PCA before (Savli et al., 2002; Engl 
et al., 2006; Ao et al., 2007). Akashi et al. showed 
that the expression of androgen receptor (AR) 
down-regulates the migratory responses of human 
PCA cells via chemokine and its receptor systems 
(Akashi et al., 2006). AR is an important molecule 
in the development of a normal prostate and PCA 
progress (George, 2003). Amplification of the AR 
gene has been described in more than 30% of 
tumors to prior to therapy (Nelson et al., 1999). 
Thus, it was reasonable to suppose that chemo-
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Figure 2. Network contains down- 
regulated genes and identified 
around NFKB gene. Top functions 
of the genes were related to cel-
lular assembly and organization, 
connective tissue development and 
function, neurological disease. 
Node (gene) and edge (gene rela-
tionship) symbols were described 
in the bottom part of the figure. The 
intensity of the node color (green) 
indicated the degree of down- 
regulation. Genes in uncolored 
notes were not identified as differ-
entially expressed in our experi-
ment and were integrated into the 
computationally generated net-
works on  the basis of the evidence 
stored in the IPA knowledge memo-
ry indicating a relevance to this 
network. The node shapes denote 
enzymes ( ), phosphatases ( ), 
kinases ( ), peptidases ( ), 
G-protein coupled receptor ( ), 
transmembrane receptor ( ), cyto-
kines ( ), growth factor ( ), ion 
channel ( ), transporter ( ), 
translation factor ( ), nuclear re-
ceptor ( ), transcription factor 
( ) and other ( ).
Table 4. List of the genes in most significantly down-regulated top ten canonical pathways.
Pathway -log (P-value) Ratio Molecules
Axonal Guidance Signaling 1,16E+01 4,89E-02
PIK3C2B, NGEF, RGS3, SEMA5A, RAC1, KRAS, PLXNA2, GNA14, 
ROR1 (includes EG:4919), EPHB6, FGFR3, NFAT5, ARPC2, 
ARHGEF6, GNAO1, ABLIM3, ERBB2, SEMA4B, RTN4R, PPP3CA
Arachidonic Acid Metabolism 1,00E+01 5,69E-02 GRN, LTA4H, PTGES2, AKR1C3, CYP19A1, PLA2G10, GPX2, CYP4Z1, CYP4F3, CYP2J2, ALOX5, CYP2D9
LPS/IL-1 Mediated Inhibition of 
RXR Function 9,31E+00 6,77E-02
GSTP1, MGMT, ALDH1L1, ABCG1, SULT1A2, MAOB, FABP5, 
ACSL5, ALAS1, FABP4, HS3ST1, ABCC3, RXRA
ERK/MAPK Signaling 7,94E+00 5,91E-02 PPARG, FGFR3, MYC, PIK3C2B, PPP2CB, ELF3, PLA2G10, PPP2R2B, RAC1, DUSP4, KRAS, ROR1 (includes EG:4919)
Xenobiotic Metabolism Signaling 7,85E+00 5,18E-02 PIK3C2B, GSTP1, UGT1A6, MGMT, ALDH1L1, KRAS, SULT1A2, PPP2CB, MAOB, PPP2R2B, HS3ST1, ABCC3, RXRA
Metabolism of Xenobiotics by 
  Cytochrome P450 7,59E+00 4,69E-02
GSTP1, AKR1C3, UGT1A6, DHRS2 (includes EG:10202), CYP19A1, 
CYP4Z1, ADH1B, ALDH1L1, CYP2J2, CYP2D9
Antigen Presentation Pathway 6,83E+00 1,54E-01 HLA-DRB4, HLA-A, HLA-G, HLA-DRB5, HLA-F, HLA-C
Eicosanoid Signaling 6,53E+00 8,33E-02 GRN, LTA4H, PTGES2, AKR1C3, PLA2G10, ALOX5, DPEP2
Ephrin Receptor Signaling 6,13E+00 4,81E-02 EPHB6, FGFR3, NGEF, RGS3, ARPC2, GNAO1, RAC1, KRAS, GNA14, ROR1 (includes EG:4919)
Actin Cytoskeleton Signaling 6,07E+00 4,28E-02 FGFR3, PIK3C2B, ACTB, ARPC2, FGF9, ARHGEF6, RAC1, KRAS, ROR1 (includes EG:4919), BDKRB1, TMSB4X
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kines and their ligands were highly important in the 
progression to PCA. Here we present a group of 
chemokine up-regulation in the most significant 
gene work of our study.
    The SELE gene was a highly up-regulated 
member of the network around the IL-1β  gene. 
Bhaskar et al. (2003) found up-regulated SELE 
levels in another microarray study on PCA. The 
role of this gene has been described in metastatic 
prostate tumor cells as well (Dimitroff et al., 2004). 
Other adhesion molecules (Selectin P, desmolin, 
Endothelin1, Endothelin RecA, vimentin, PECAM- 
1, etc.) were not identified on this network, but they 
were up-regulated in our study as well.
    Three serum amyloid protein coding genes 
(SAA, SAA1, SAA2) were highly up-regulated in 
the network around the IL-1β  gene. Alterations in 
the expression of serum amyloid proteins have 
been linked to many tumors such as osteosarcoma 
(Kovacevic et al., 2008), lung cancer (Dai et al., 
2007), renal cell carcinoma (Engwegen et al., 
2007), gastric cancer (Chan et al., 2007), and 
choriocarcinoma (Kovacevic et al., 2007). Serum 
amyloid protein coding genes are not specific mar-
kers for any particular type of tumor. We recom-
mend these genes for monitoring disease activity 
and response to therapy in patients with PCA.
    One network was identified around the insulin- 
like growth factor 1 (IGF-1) gene (Figure 1). This 
gene has been linked to PCA before (Abate-Shen 
and Shen, 2000). Other growth factors (IGFB7, 
GHBP, URG, and PDF) were not identified on this 
network, but they were up-regulated in our study.
    Another network was identified around the 
NFKB gene (Figure 1). The angiotensin II receptor 
type 1 gene was highly up-regulated. This gene 
could also be a good target for the therapy of 
prostate cancer (Uemura et al., 2006). Further 
studies are required to establish the role this gene 
plays in PCA.
    Our study has also demonstrated up-regulated 
apoptosis related genes (FAS, BIC, PACAP, BFL1) 
and up-regulated oncogene partners (PET-1, LAF- 
4, HSP2123-like). FAS is the most conspicuous 
gene among them. Up-regulated FAS levels were 
reported in PCA previously (Iacopino et al., 2006). 
Well-known oncogenes such as Ras (Konishi, 
1992), or apoptosis related genes such as BCL2 
(McDonnell, 1992) were found in PCA progress 
previously, but we did not confirm them in this 
study.
    Canonical pathway analysis revealed that “acute 
phase response” was the most significant signaling 
pathway modulated by the up-regulated genes in 
PCA (See Supplementary Figure 1). Dysregulation 
of IL-6-type cytokine signaling was reported to 
contribute to PCA previously (Heinrich et al., 2003). 
The genes that we found up-regulated were using 
the IL1 type cytokine signaling on an extracellular 
level. Then, interactions were determined among 
p38 MAPK and c-fos in the nucleus, but it is not 
easy to determine the pathway that really par-
ticipated in prostate tumorigenesis since many 
other pathway members were not detected.
    Another significant signaling pathway is hepatic 
fibrosis/hepatic stellate cell activation (See Sup-
plementary Figure 3). Changes in prostate-specific 
antigen levels among cirrhotic patients have been 
reported before (Kubota et al., 1999; Akdogan et 
al., 2002) but further research is needed to est-
ablish whether these genes are new molecular 
markers or not.
    The actin cytoskeleton pathway was highly sig-
nificant. This pathway has been reported many 
times in PCA before (Moore et al., 2000; Papa-
konstanti et al., 2003; Wells et al., 2005; Marelli et 
al., 2006). Genes belonging to the coagulation 
pathway were found to be distinctly up-regulated 
(See Supplementary Figure 2). Patients with PCA 
may have life-threatening coagulation complica-
tions due to their disease. The pathophysiology of 
disseminated intravascular coagulopathy in pa-
tients with prostate cancer is not completely under-
stood. Investigators reported coagulation disorders 
as early or late signs in PCA (Bern, 2005; Navarro 
et al., 2006; Duran and Tannock, 2007; Shirai and 
Chaudhary, 2007). We found highly up-regulated 
F8, F5, F9, VWF, and F3 gene accumulation 
around ca-dependent and ca-phospholipid depen-
dent regions of the coagulation pathway. These 
regions could be the subject of studies to un-
derstand the pathophysiology and plan further 
therapeutic interventions.
    Analysis using IPA software revealed that 515 
mapped down-regulated genes were detected in 
the progression to PCA. These were 363 network 
eligible genes and 342 Functions-Pathways eligi-
ble genes. Often individual genes were found in 
multiple categories of functions related to cell-to- 
cell signaling and interaction, cell signaling, im-
mune response, cancer, cellular growth and pro-
liferation, nucleic acid metabolism, cellular as-
sembly and organization, and connective tissue 
development and function.
    One important down-regulated carcinogenic gene 
network was identified around the NFKB gene 
(Figure 2). We observed some down-regulated 
genes, ADRA2C, FABP4, and FABP5, which were 
not reported in cancer progress before. Moreover, 
five genes belonging to MHC were strictly down- 
regulated in this network (H2-Q10, HLA-A, HLA-C, 
HLA-F, and HLA-G). Tamura et al. (2007) observed 
Pathway analysis in prostate cancer    183
down-regulation of HLA-A antigen in microarray 
analysis of hormone-refractory prostate cancer. We 
report the down-regulation of four genes (H2-Q10, 
HLA-C, HLA-F, and HLA-G) here for the first time.
    Canonical pathway analysis revealed that “anti-
gen presentation” was an important pathway mod-
ulated by the down-regulated genes in PCA. Our 
findings on MHC genes were related to down-re-
gulation of MHC I-α  and MHC II-β  class genes 
(See Supplementary Figure 4). 
    Axonal guidance signaling was the most signi-
ficant down-regulated canonical pathway (See Sup-
plementary Figure 5). The FGFR3 gene showed the 
highest value of under-expression. Fibroblast growth 
factors (FGFs) and their receptors (FGFRs) have a 
critical function for the development and home-
ostasis of the human prostate. Imbalance in ex-
pression of these factors is associated with mali-
gnancy. We found three members of this family 
(FGFR3, PIK3C2B, and RAC1) to be down- 
regulated. RAC1 and FGFR3 were evaluated in 
previous studies (Kwabi-Addo et al., 2001; 
Gowardhan et al., 2005; Chaffer et al., 2007; Wu et 
al., 2007), but here we report PIK3C2B gene 
down-regulation and its relationship to PCA for the 
first time.Two important gene members of this 
pathway were down-regulated. K-RAS is not only 
an oncogene, but also a known target in differ-
entiation therapy of PCA (Benbrahim-Tallaa et al., 
2005, 2007). ERBB2 overexpression is important 
in PCA and our finding is in concordance with 
previous observations (Liu et al., 2001; Calvo et 
al., 2003; Ullén et al., 2005). Taken together, two 
well-known genes, FOS and IL1B, were up- 
regulated as members of the same pathway as 
well. Axonal guidance signaling in the progress of 
PCA needs further investigation. 
    There are different valuable bioinformatic ap-
proaches in the literature to analyze prostate can-
cer progression. Tomlins et al. (2007) profiled pro-
state cancer progression from benign epithelium to 
metastatic disease. They identified expression sig-
natures, and analyzed these signatures in the 
context of a compendium of molecular concepts. 
Their strategy allowed them to make several 
insights into disease progression. In the present 
study we analyzed over one thousand altered 
genes regarding functions and communications 
using the IPA tool and detected new relationships. 
    Our data provide not only new networks bet-
ween the genes for understanding the biologic 
properties of PCA but also useful common path-
way maps for future understanding of disease and 
construction of new therapeutic targets. Further 
combined genomic and proteomic studies are ne-
cessary to find out more details of the hierarchy 
and regulation on DNA-RNA-protein levels.
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